Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
we are no longer hearing that the fmcc fnma is a failed business model.- new administration position
shift of sentiment regarding fnma and fmcc. new administration stand.
did the president knew the true or he was mislead by his subordinate. 56 document will prove. that is what plaintiff is trying to release
if breach of contract can be proved the restitution is going to be 20 dollar a share for the preferred seris
fhfa acted as a genunine conservator? main argument for the plaintif.
308 cases have been heard .304 has been settled. we are coming very close. we are 4 cases away from receive the opinion. according to the litigation attorney of plaintiff
quite optimistic with new administration of fnma adn fmcc. Bruce Berkowitz states
goverment sponsored expropriation biggest in history. Bruce Berkowitz states
fnam and fmcc two best business in world. Bruce Berkowitz states
fairholm started. attorney for fnam litigation is there
fairholm conference in about 4 minutes
Fannie Mae – Holding Steady on Ending the Conservatorship and Restoring Shareholder Rights
http://www.valuewalk.com/2016/11/fannie-mae-ending-conservatorship/
“The conservatorship of Fannie Mae and Freddie Mac was never supposed to last this long, and it has opened the door for lawless behavior by our government,” Investors Unite founder Tim Pagliara said in statement. “We hope the election creates the conditions to end the conservatorship and for a legal settlement with investors, either now or in early 2017.”
warnings about the ongoing depletion of the GSEs’ capital base will require the attention of senior officials early on in the incoming Administration. It is unlikely President-elect Trump relishes the idea of seeking taxpayer assistance to shore up Fannie and Freddie. The hasty dismantling of enterprises that have been the bedrock of affordable homeownership for generations of working families will not likely engender support from the public.
Since Fannie and Freddie were put into conservatorship eight years ago, dozens of ideas have been offered to dismantle the GSEs and create a better housing finance. Most have failed to gain traction. One reason for this is that most do not represent a better way to provide countercyclical liquidity and stability in the mortgage market. A new Administration represents a chance to take a fresh look at options. It should not be a reason to start from scratch in designing solutions and extend a conservatorship that has already gone on for too long. It is time to restore shareholders’ rights and release recapitalized and reformed GSEs to perform their invaluable service to hard-working American families.
i did a internet search and only found AIG share sold by fairholms. did not find any BAC
Carl Icahn Joins Bill Ackman In Bet On Fannie And Freddie
Carl Icahn appears to have joined the hedge fund party that is trying to make a fortune off of the resuscitation of mortgage giants Fannie Mae and Freddie Mac, the government sponsored enterprises that were bailed out during the financial crisis and placed into conservatorship.
Icahn took a $50 million position in Fannie Mae and Feddie Mac in March by buying common stock from Bruce Berkowitz’s Fairholme Funds. Icahn bought 6.8 million shares of Fannie Mae for $4.03 per share and 5.7 million shares of Freddie Mac for $4.04 per share, according to a court document that was reported by The Wall Street Journal and CNBC. Berkowtiz, who bet early and big on Fannie and Freddie, not only gets to book a nice gain on the shares he sold to Icahn, but he potentially also gets an ally in his effort to make outsized gains from his continued large position in both the common and preferred shares of the GSEs
http://www.forbes.com/sites/nathanvardi/2014/06/03/carl-icahn-joins-bill-ackman-in-bet-on-fannie-and-freddie/#7f623b93326b
Over the past few years, Paulson and other hedge fund investors have deployed an intense lobbying and public relations campaign in Washington over a variety of issues that would benefit their bottom line. This included heavy lobbying to make sure debts Puerto Rico owed to their hedge funds were first in line for full repayment and getting the federal government to release Fannie and Freddie.
Joining Paulson on the Trump transition team is another supporter of his favored Fannie and Freddie policy: former Ohio Secretary of State Kenneth Blackwell. The far-right politician was tapped to lead Trump’s domestic policy transition team. In 2014, while working for a nonprofit founded by investors in Fannie and Freddie stock, he penned many op-eds calling for the hedge fund-backed policy of recapitalization and release
Trump has routinely sided with the hedge fund campaigns throughout the campaign. The Republican Party platform enacted at the Republican National Convention in Cleveland included support for the recapitalization and release of Fannie and Freddie. He also endorsed the hedge fund campaign to pressure Puerto Rico to pay back debts to them first.
His election victory is already paying off for Paulson. The billionaire’s hedge fund saw a massive gain of $463 million on Wednesday on the strength of its investments in pharmaceutical companies. That is only the beginning of the windfall Trump’s election provides to his billionaire donors
http://www.huffingtonpost.com/entry/donald-trump-hedge-fund_us_5826076ce4b02d21bbc8781e
Frannie investors liking makeup of Trump team
• Fannie Mae (OTCQB:FNMA +7.9%) and Freddie Mac (OTCQB:FMCC +9.2%) are now both doubles since the election results on hopes the "profit sweep" may soon be history.
• Picked to lead the domestic transition team, Ken Blackwell two years ago called the arrangement with Treasury "theft of private property."
• John Paulson has reportedly been tapped as an advisor, and he's known to be a fan of releasing government sponsored enterprises from their shackles.
• Former Goldmanite Steven Mnuchin was Trump's campaign finance chief and apparently on the short list for Treasury Secretary. While he's not been explicit about his views on Frannie, he does serve on the Sears board with Fairholme's Bruce Berkowitz and is seen as likely sympathetic to shareholder interests.
• Bill Ackman: "I think Fannie and Freddie are going to get resolved within the first 12 months of this new administration, and I’m looking forward to having my second meeting with Donald Trump and negotiating a deal."
http://www.investing.com/news/stock-market-news/frannie-investors-liking-makeup-of-trump-team-440043
this stock is not dictated by chart but rather events. the possibility of being released from conservatorship. any indication of that is the catalyst for spike.
Over the past few years, Paulson and other hedge fund investors have deployed an intense lobbying and public relations campaign in Washington over a variety of issues that would benefit their bottom line. This included heavy lobbying to make sure debts Puerto Rico owed to their hedge funds were first in line for full repayment and getting the federal government to release Fannie and Freddie.
Joining Paulson on the Trump transition team is another supporter of his favored Fannie and Freddie policy: former Ohio Secretary of State Kenneth Blackwell. The far-right politician was tapped to lead Trump’s domestic policy transition team. In 2014, while working for a nonprofit founded by investors in Fannie and Freddie stock, he penned many op-eds calling for the hedge fund-backed policy of recapitalization and release
Trump has routinely sided with the hedge fund campaigns throughout the campaign. The Republican Party platform enacted at the Republican National Convention in Cleveland included support for the recapitalization and release of Fannie and Freddie. He also endorsed the hedge fund campaign to pressure Puerto Rico to pay back debts to them first.
His election victory is already paying off for Paulson. The billionaire’s hedge fund saw a massive gain of $463 million on Wednesday on the strength of its investments in pharmaceutical companies. That is only the beginning of the windfall Trump’s election provides to his billionaire donors
http://www.huffingtonpost.com/entry/donald-trump-hedge-fund_us_5826076ce4b02d21bbc8781e
Frannie investors liking makeup of Trump team
• Fannie Mae (OTCQB:FNMA +7.9%) and Freddie Mac (OTCQB:FMCC +9.2%) are now both doubles since the election results on hopes the "profit sweep" may soon be history.
• Picked to lead the domestic transition team, Ken Blackwell two years ago called the arrangement with Treasury "theft of private property."
• John Paulson has reportedly been tapped as an advisor, and he's known to be a fan of releasing government sponsored enterprises from their shackles.
• Former Goldmanite Steven Mnuchin was Trump's campaign finance chief and apparently on the short list for Treasury Secretary. While he's not been explicit about his views on Frannie, he does serve on the Sears board with Fairholme's Bruce Berkowitz and is seen as likely sympathetic to shareholder interests.
• Bill Ackman: "I think Fannie and Freddie are going to get resolved within the first 12 months of this new administration, and I’m looking forward to having my second meeting with Donald Trump and negotiating a deal."
http://www.investing.com/news/stock-market-news/frannie-investors-liking-makeup-of-trump-team-440043
still it is fnma. He had or has vested interest on it.
as of 20!5 JUL 1 5 PH 4: 1 4 trump was holding fnma worth 500000-1000000
http://stocktwits.com/symbol/FNMA?q=FNMA
http://www.huffingtonpost.com/entry/donald-trump-hedge-fund_us_5826076ce4b02d21bbc8781e
Over the past few years, Paulson and other hedge fund investors have deployed an intense lobbying and public relations campaign in Washington over a variety of issues that would benefit their bottom line. This included heavy lobbying to make sure debts Puerto Rico owed to their hedge funds were first in line for full repayment and getting the federal government to release Fannie and Freddie.
Joining Paulson on the Trump transition team is another supporter of his favored Fannie and Freddie policy: former Ohio Secretary of State Kenneth Blackwell. The far-right politician was tapped to lead Trump’s domestic policy transition team. In 2014, while working for a nonprofit founded by investors in Fannie and Freddie stock, he penned many op-eds calling for the hedge fund-backed policy of recapitalization and release
Trump has routinely sided with the hedge fund campaigns throughout the campaign. The Republican Party platform enacted at the Republican National Convention in Cleveland included support for the recapitalization and release of Fannie and Freddie. He also endorsed the hedge fund campaign to pressure Puerto Rico to pay back debts to them first.
His election victory is already paying off for Paulson. The billionaire’s hedge fund saw a massive gain of $463 million on Wednesday on the strength of its investments in pharmaceutical companies. That is only the beginning of the windfall Trump’s election provides to his billionaire donors
http://www.marketwatch.com/story/how-donald-trumps-win-could-affect-your-wallet-2016-11-10
How Donald Trump’s Win could affect your wallet
The fact that Fannie Mae FNMA, +27.92% and Freddie Mac FMCC, +26.32% shares saw a slight bump on Wednesday may indicate a sentiment that a Trump administration would allow them to build capital, Mayer said.
If Trump can create more aggressive growth in the U.S. economy, that may have the biggest impact on housing, Hamrick said.
See paragraph Housing
salt lake city company finding success with cannabis for canines
http://fox13now.com/2016/11/09/salt-lake-city-company-finding-success-with-cannabis-for-canines/
what legalized recreational marijuana can mean for food and beverage
http://www.foodnavigator-usa.com/Regulation/What-legalized-recreational-marijuana-can-mean-for-food-and-beverage
New Zealand Grants License for Third Hemp Trial
https://www.ganjapreneur.com/new-zealand-grants-license-third-hemp-trial/
Investing in #Marijuana and #Hemp #Stocks; The Market Gets Bigger Following Election
November 9, 2016 (Investorideas.com Newswire) Investorideas.com, a global news source and investor resource issues an updated directory and news alert for Marijuana and Hemp Stocks following the US election and the legalization in new States
http://www.investorideas.com/news/2016/marijuana/11091Election.asp
Hemp is getting hotter, with help and harm from marijuana
http://www.marketwatch.com/story/hemp-is-getting-hotter-with-help-and-harm-from-marijuana-2016-11-08
It has been up for few days. No new good news coming until early next year. Now it is time to take the profit, this is the law of biopharma stock,
The Canadian biotech noted that it had $12.1 million in cash at the end of H1, leaving it looking for fresh funds with a battered stock price.
http://endpts.com/facing-questions-on-patient-deaths-aurinia-shares-crater-in-wake-of-phiib/
noted at the end of the article
--- this might be a catalyst for new public offering.
research and development expenses were $3.3 million for the three months ended June 30, 2016
http://thevillagessuntimes.com/2016/08/18/aurinia-pharmaceuticals-inc-auph-rating-reiterated-by/
The Aurinia team is focused on preparations for the AURA primary end point data release expected prior to the end of August, 2016, and initiation of the Phase 3 program in 2017. The Company is making the necessary investments now to ensure the team has the tools to deliver future success. The remainder of the year will also see further data releases from the AURION study including additional 24 week data points.
The Company is also in the process of completing assessments of key markets in the Americas, Europe and Asia. The Company will share more on these developments during future investor presentations.
"We are fast approaching a pivotal event for Aurinia with primary endpoint data from the AURA trial expected very soon. The Aurinia team is excited to have reached this stage in the development of voclosporin for lupus nephritis. We plan to continue to execute on initiatives to maximize shareholder value and help bring a desperately needed therapy to market for patients suffering from this disease," said Charlie Rowland, CEO of Aurinia Pharmaceuticals Inc. Operational and Corporate Developments AURA Phase 2b Clinical Trial Update On January 19, 2016, the Company announced completion of patient enrollment of its AURA Phase 2b clinical trial at 265 patients (the target number of patients was 258).
http://www.pharmacychoice.com/news/article.cfm?Article_ID=1601985
: We gained some important perspective on the death rate patterns in the AURA-LV trial from speaking with management after its conference call that just ended, which makes us incrementally more comfortable that the FDA will view the risk/ benefit of voclosporin favorably. We believe that AUPH shares would not be trading down so precipitously (if at all) if this were made clearer. Reiterate OP on AUPH. • All of the deaths occurred in much less developed places including Bangladesh, Sri Lanka and Russia, and no Americans died in the study. Management believes that standard of care in these sites is actually very good, but the patients definitely have a much more severe course of disease when they present for care. Management expects to account for this dynamic when conducting the Phase III study for voclosporin.
https://portal.leerink.com/IRPDocumentViewer/Web/DocumentViewerCache.aspx?docId=367470386B7262635848343D&pad=6A37305A6E4267526F456B32466E7748366B51624C413D3D&userId=56715736387362644D48383D
Bio Roundup
in Phase 2, Aurinia Pharmaceuticals (NASDAQ: AUPH) of Victoria, BC, said its lupus nephritis drug voclosporin hit its primary goal, driving more patients into remission than the standard of care. But investors hammered
Aurinia shares because 13 patients died in the trial. The company said the deaths mainly occurred in Asia, and that the doctor running the trialreported them as unrelated to the treatment
http://www.xconomy.com/national/2016/08/19/bio-roundup-fda-says-no-pcsk9-value-fight-crispr-intrigue-more/2/#
Recent Research Analysts’ Ratings Updates for Aurinia Pharmaceuticals (AUPH)
Several brokerages have updated their recommendations and price targets on shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) in the last few weeks:
8/17/2016 – Aurinia Pharmaceuticals had its price target raised by analysts at HC Wainwright from $7.00 to $10.00. They now have a “buy” rating on the stock.
8/16/2016 – Aurinia Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann.
8/15/2016 – Aurinia Pharmaceuticals had its “outperform” rating reaffirmed by analysts at FBR & Co. They now have a $9.00 price target on the stock.
8/5/2016 – Aurinia Pharmaceuticals was given a new $10.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
7/6/2016 – Aurinia Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $7.00 price target on the stock.
6/30/2016 – Aurinia Pharmaceuticals is now covered by analysts at HC Wainwright. They set a “buy” rating and a $7.00 price target on the stock.
http://www.americanbankingnews.com/2016/08/19/recent-research-analysts-ratings-updates-for-aurinia-pharmaceuticals-auph/
Consensus Watch on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
Equity research analysts have provided views on where they believe Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) will be trading in the future. According to Thomson Reuters, analysts are projecting a consensus target price of $7.80 on company shares. Sell-side analysts tap into their vast knowledge of the company to help gauge future stock movement. Because of the various techniques used, analysts may come up with very different stock target estimates.
http://presstelegraph.com/2016/08/19/consensus-watch-on-aurinia-pharmaceuticals-inc-nasdaqauph/
• Analysts watching two Stocks: StemCells, Inc. (NASDAQ:STEM) , Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) after beginning at $2.41, closed at $2.26 by cutting down -7.38% in recent trading session. Most recent session’s volume of 2.2 million shares greater than its average volume of 691.36 thousand shares. The company has market value of $79.75M.
Analysts have consensus one year price target of $7.80.
During the last trading session, the stock’s price changed -18.64% below its 200 day moving average of $2.78 and moving -28.34% downbeat it’s SMA 50 of $3.15.
What Analysts Say about this Stock:
The Company has received rating from WSJ analysts. 1 Month Ago, the stock has been rated as “Buy” from 4 Analysts. 0 analysts have suggested “Sell” for the company. 0 analysts have rated the company as a “Hold”. Overweight rating was given by 0 analysts and Underweight rating was given by 0 analysts. The stock has received “BUY” rating after consensus analysis from analysts.
http://www.streetupdates.com/2016/08/19/analysts-watching-two-stocks-stemcells-inc-nasdaqstem-aurinia-pharmaceuticals-inc-nasdaqauph/
Equities Analysts Issue Forecasts for Aurinia Pharmaceuticals Inc.’s Q4 2016 Earnings (AUPH)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) – Analysts at FBR & Co issued their Q4 2016 earnings per share estimates for Aurinia Pharmaceuticals in a research report issued on Wednesday. FBR & Co analyst V. Bernardino forecasts that the brokerage will post earnings per share of ($0.13) for the quarter. FBR & Co currently has a “Outperform” rating and a $9.00 target price on the stock. FBR & Co also issued estimates for Aurinia Pharmaceuticals’ FY2020 earnings at ($0.01) EPS.
http://zolmax.com/investing/equities-analysts-issue-forecasts-for-aurinia-pharmaceuticals-inc-s-q4-2016-earnings-auph/881414.html
Aurinia Pharmaceuticals (AUPH) Plunges Despite Upbeat Trial Data
What should have been a big win for Aurinia Pharmaceuticals Inc.'s stock (NASDAQ:AUPH) Monday on the back of positive phase IIb data in the particularly tough lupus nephritis (LN) indication turned into a drubbing for the shares, which plunged 56 percent as investor attention focused - perhaps unfairly - on the study's death rate.
http://tjcnewspaper.com/aurinia-pharmaceuticals-auph-plunges-despite-upbeat-trial
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm246489.htm
The currently approved drug is Benlysta (belimumab) to treat patients with active, autoantibody-positive lupus.
Lupus is a serious, potentially fatal, autoimmune disease that attacks healthy tissues.
Two clinical studies involving 1,684 patients with lupus demonstrated the safety and effectiveness of Benlysta. Patients treated with Benlysta and standard therapies experienced less disease.
Results suggested, but did not definitively establish, that some patients had a reduced likelihood of severe flares. Those receiving Benlysta during clinical studies reported more deaths and serious infections .
Now with auph. recent trial. In the study, 32.6% of patients on low dose achieved complete remission, compared to 27.3% on high dose. According to a company statement, the drug reached its primary endpoint of achieving greater complete remission in the trial
Forty percent of all the patients in the study were enrolled in Asia. The deaths were not related to the drug, might be attributed to the kind of treatment standards in daily practice in Asia.
Conclusion. Auph trial drug is much more effective drug than the currently approved regimen.
A response from the Aurinia Pharmaceuticals Inc public relation:
[img]Enamul Khan
Dear Sir/madam, I am writing to request for some more information regarding t...
11:32 AM (45 minutes ago)
Celia Economides <ceconomides@auriniapharma.com>
12:05 PM (13 minutes ago)
to me
Dear Enamul,
I’m the head of IR for Aurinia. Thank you for being a shareholder in the company and for your confidence in our results. We feel the same! I’ll point you to the press release that was issued on Monday: http://www.auriniapharma.com/dnn/LinkClick.aspx?fileticket=ifNeeSftXPk%3d&tabid=41&mid=570
It is clearly stated in the press release under safety: “There were 13 deaths across the trial: (2) in the high-dose voclosporin arm; (10) in the low-dose voclosporin arm (10); and (1) in the control arm, with the majority of overall deaths (11/13) occurring in Asia. All deaths were assessed by the Investigator as being unrelated to study treatment. No dose relationship was observed for the deaths.”
Furthermore, this was stated in our conference call prepared remarks: “Lastly, we know this is a serious and life-threatening disease, so deaths are largely expected across LN studies, which is an unfortunate part of treating this disease and somewhat unavoidable. Across the study, there were 13 deaths, with 11/13 occurring in Asia. The voclosporin high-dose arm has (2), the low-dose arm had (10) and the control arm had (1). ALL deaths were assessed by the Investigator as being UNRELATED to study treatment. There was no dose relationship observed for the deaths that occurred in the study.”
Lastly, as stated in our conference call, we will be updating the investment community with more data (once available) around the AURA study in the September/October time frame.
Thank you,
Celia[/img]